Reiseimpfungen

Key words

travel medicine - travel vaccines - immunocompromised travelers - paediatric travelers - pregnant travelers

Publication History

Article published online:
06 December 2024

• Literatur

• 1 Ständige Impfkommission und Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. unter besonderer Mitarbeit von Kling K, Külper-Schiek W, Rothe C et al. Empfehlungen der Ständigen Impfkommission (STIKO) und der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. (DTG) zu Reiseimpfungen. Epid Bull 2023; 14: 1-193
• 2 Steffen R, Behrens RH, Hill DR. et al Vaccine-preventable travel health risks: what is the evidence – what are the gaps?. J Travel Med 2015; 22: 1-12
• 3 Connor BA, Dawood R, Riddle MS. et al Cholera in travellers: a systematic review. J Travel Med 2019; 26: pii-taz085
• 4 World Health Organization. Poliovirus IHR Emergency Committee 2024. Im Internet:. https://www.who.int/groups/poliovirus-ihr-emergency-committee
• 5 World Health Organization. International Travel and Health – 18 November 2022, Revised on 3 January 2023. Country List – Country vaccination requirements and WHO recommendations for vaccination against yellow fever, poliomyelitis, and malaria prophylaxis in international travellers. 2022 ed. Geneva: WHO; 2022: 46.
• 6 The Embassy of the Kingdom of Saudi Arabia. Hajj and Umrah Health Requirements. Im Internet:. https://www.saudiembassy.net/hajj-and-umrah-health-requirements
• 7 Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit. Weltwärts-Untersuchungen. Im Internet:. https://www.dtg.org/index.php/liste-tropenmedizinischer-institutionen/weltwaerts-informationen-fueraerzte.html
• 8 Ständige Impfkommission: Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2024. Epid Bull 2024; 4: 1-72
• 9 Piechotta V, Koch J, Berner R. et al Aktualisierung der COVID-19-Impfempfehlung in den allgemeinen Empfehlungen der STIKO 2024 und die dazugehörige wissenschaftliche Begründung. Epid Bull 2024; 2: 3-19
• 10 Harris A, Hepatitis B. In: CDC (Ed.). Yellow Book 2024. Oxford University Press: Section 5. Im Internet: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/hepatitis-b
• 11 Heyward WL, Kyle M, Blumenau J. et al Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine 2013; 31: 5300-5305
• 12 Vesikari T, Langley JM, Segall N. et al Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2021; 21: 1271-1281
• 13 Steffen R, Chen LH, Leggat PA. Travel vaccines-priorities determined by incidence and impact. J Travel Med 2023; 30: taad085
• 14 Hirve S, Newman LP, Paget J. et al Influenza Seasonality in the Tropics and Subtropics – When to Vaccinate?. PLoS One 2016; 11: e0153003
• 15 Laws JH, Baumann U, Bogdan C. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 588-644
• 16 Bundeszentrale für gesundheitliche Aufklärung. Masernschutz.de. Im Internet:. https://www.masernschutz.de
• 17 Gershman M, Staples JE. Yellow Fever. In: CDC (Ed.). Yellow Book 2024. Oxford University Press: Section 5. Im Internet:. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/yellow-fever
• 18 Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol 2015; 64: 160-173
• 19 NaTHNaC. Yellow fever vaccine recommendation maps. Im Internet:. https://nathnacyfzone.org.uk/factsheet/60/yellow-fever-vaccine-recommendation-maps
• 20 Kling K, Bogdan C, Burchard G. et al STIKO-Empfehlung zur Gelbfieber-Auffrischimpfung vor Reisen in Endemiegebiete und für exponiertes Laborpersonal. Epid Bull 2022; 32: 3-35
• 21 Kling K, Domingo C, Bogdan C. et al Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis. Clin Infect Dis 2022; 75: 2266-2274
• 22 Schnyder JL, de Jong HK, Bache BE. et al Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis. Lancet Glob Health 2024; 12: e445-e456
• 23 Gnanadurai R, Campo-Matos I, Kanagarajah S. et al National review of reported Yellow fever vaccine incidents in the UK. Travel Med Infect Dis 2022; 102289
• 24 Staples JE, Monath TP, Gershman MD, Barrett ADT. Yellow Fever Vaccines. In: Orenstein W, Offit P, Edwards KM, Plotkin S (Eds.). Plotkin’s Vaccines. 7^th ed. Philadelphia: Elsevier; 2017: 1181-1265
• 25 StAR. Aufklärungsmerkblatt, Fragebogen und Einverständniserklärung vor Impfung gegen Gelbfieber. Im Internet:. https://www.dtg.org/images/Startseite-Download-Box/Gelbfieber-Aufklaerung_DTG_STAR_0223.pdf
• 26 Bwaka A, Bita A, Lingani C. et al Status of the rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018. J Infect Dis 2019; 220 (Suppl 4) S140-S147
• 27 Peterson ME, Li Y, Bita A. et al Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health 2019; 9: 010409
• 28 Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis 2012; 25: 507-517
• 29 Memish ZA, Goubeaud A, Bröker M. et al Invasive meningococcal disease and travel. J Infect Public Health 2010; 3: 143-151
• 30 Steffen R. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med 2010; (17) Suppl 9-17
• 31 Ruiz Garcia Y, Abitbol V, Pellegrini M. et al A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine. Infect Dis Ther 2022; 11: 639-655
• 32 Haidara FC, Umesi A, Sow SO. et al Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia. N Engl J Med 2023; 388: 1942-1955
• 33 Peterson J, Drazan D, Czajka H. et al Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. Lancet Infect Dis 2023; 23: 1370-1382
• 34 Steffen R, Caumes E. Three novel pentavalent meningococcal vaccines. J Travel Med 2024; 31: taad152
• 35 World Health Organization. Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt, January 2024. Weekly Epidemiological Record; 12 January 2024.
• 36 Ministry of Health, Kingdom of Saudi Arabia. Health Requirements and Recommendations for Travelers to Saudi Arabia for Hajj – 1445H (2024). Im Internet:. https://www.moh.gov.sa/en/HealthAwareness/Pilgrims_Health/Documents/Health-Regulations-En.pdf
• 37 World Health Organization. Vaccination schedule for Meningococcal disease. Im Internet:. https://immunizationdata.who.int/pages/schedule-by-disease/meningococcal.html
• 38 Piechotta V, Koch J, Bogdan C. et al Empfehlung zur Standardimpfung von Säuglingen gegen Meningokokken der Serogruppe B und die dazugehörige wissenschaftliche Begründung. Epid Bull 2024; 3: 3-32
• 39 World Health Organization. Statement following the Thirty-ninth Meeting of the IHR Emergency Committee for Polio. 13 August 2024. Im Internet:. https://www.who.int/news/item/13-08-2024-statement-of-the-thirty-ninth-meeting-of-the-polio-ihr-emergency-committee
• 40 World Health Organization. Global Circulating Vaccine-derived Poliovirus (cVDPV). 20.February 2024. Im Internet:. https://polioeradication.org/wp-content/uploads/2024/02/weekly-polio-analyses-cVDPV-20240220.pdf
• 41 Konopka-Anstadt JL, Campagnoli R, Vincent A. et al Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines 2020; 5: 26
• 42 Global Polio Eradication Initiative. GPEI press release on nOPV2 prequalification. 09/01/2024. Im Internet:. https://polioeradication.org/news-post/gpei-press-release-on-nopv2-prequalification/
• 43 Steffen R, Acar J, Walker E. et al Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med Infect Dis 2003; 1: 80-88
• 44 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch für 2020. Berlin: 2021
• 45 Nürnberg M, Equihua Martinez G, Jacob D. et al Two cases of imported cholera in Germany after short business travel to Yaoundé, Cameroon. J Travel Med 2023; 30: taad098
• 46 McCarty JM, Cassie D, Bedell L. et al Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States. Am J Trop Med Hyg 2021; 104: 1758-1760
• 47 McCarty J, Bedell L, De Lame PA. et al Update on CVD 103-HgR single-dose, live oral cholera vaccine. Expert Rev Vaccines 2022; 21: 9-23
• 48 Collins JP, Ryan ET, Wong KK. et al Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022. MMWR Recomm Rep 2022; 71: 1-8
• 49 World Health Organization. Dengue and severe dengue. 17 March 2023. Im Internet:. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
• 50 Deutsche Gesetzliche Unfallversicherung. BK 3102. Im Internet:. https://www.dguv.de/bk-info/icd-10-kapitel/kapitel_01/bk3102/index.jsp
• 51 Sanchez-Vegas C, Hamer DH, Chen LH. et al Prevalence of dengue virus infection in US travelers who have lived in or traveled to dengue-endemic countries. J Travel Med 2013; 20: 352-360
• 52 Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine 2017; 35: 6355-6358
• 53 Tricou V, Yu D, Reynales H. et al Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health 2024; 12: e257-e270
• 54 Tricou V, Low JG, Oh HM. et al Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine 2020; 38: 1513-1519
• 55 Kling K, Külper-Schiek W, Schmidt-Chanasit J. et al STIKO-Empfehlung und wissenschaftliche Begründung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga. Epid Bull 2023; 48: 3-43
• 56 Ständiger Ausschuss Reisemedizin der DTG. Zur Impfung gegen Denguefieber mit Qdenga^®. 16.02.2024. Im Internet:. https://www.dtg.org/index.php/aktuelles/mitteilungen-der-dtg.html
• 57 Robert Koch-Institut. FSME: Risikogebiete in Deutschland (Stand: Januar 2023). Epid Bull 2023; 9: 3-22
• 58 Van Heuverswyn J, Hallmaier-Wacker LK, Beauté J. et al Spatiotemporal spread of tick-borne encephalitis in the EU/EEA, 2012 to 2020. Euro Surveill 2023; 28: 2200543
• 59 Robert Koch-Institut. FSME-Risikogebiete in Deutschland (Stand: Januar 2024). Epid Bull 2024; 9: 3-21
• 60 European Centre for Disease Prevention and Control. Tickborne encephalitis. In: ECDC. Annual epidemiological report for 2020. Stockholm: ECDC; 2022. Im Internet: https://www.ecdc.europa.eu/en/publications-data/tickborne-encephalitis-annual-epidemiological-report-2020
• 61 Hansson KE, Rosdahl A, Insulander M. et al Tick-borne Encephalitis Vaccine Failures: A 10-year Retrospective Study Supporting the Rationale for Adding an Extra Priming Dose in Individuals Starting at Age 50 Years. Clin Infect Dis 2020; 70: 245-251
• 62 Erber W, Khan F, Zavadska D. et al Effectiveness of TBE vaccination in southern Germany and Latvia. Vaccine 2022; 40: 819-825
• 63 Nygren TM, Pilic A, Böhmer MM. et al Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany. Sci Rep 2022; 12: 11706
• 64 Steffen R, Erber W, Schmitt HJ. Can the booster interval for the tick-borne encephalitis (TBE) vaccine ‘FSME-IMMUN’ be prolonged? – A systematic review. Ticks Tick Borne Dis 2021; 12: 101779
• 65 Schmidt SM. Impfen: Was tun bei bestehenden Allergien?. Dtsch Arztebl 2018; 115 Supplement: Perspektiven der Pneumologie & Allergologie
• 66 Wiedermann-Schmidt U, Maurer W. [Adjuvants and additives in vaccines--medical relevance]. Wien Klin Wochenschr 2005; 117: 510-519
• 67 Balogun O, Brown A, Angelo DO KM. et al Acute hepatitis a in international Travelers: A GeoSentinel analysis, 2008–2020. J Travel Med 2022; taac013
• 68 Furuya-Kanamori L, Gyawali N, Mills DJ. et al The Emergence of Japanese Encephalitis in Australia and the Implications for a Vaccination Strategy. Trop Med Infect Dis 2022; 7: 85
• 69 Srivastava KS, Jeswani V, Pal N. et al Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines. Vaccines (Basel) 2023; 11: 742
• 70 Hills SL, Walter EB, Atmar RL. et al Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2019; 68: 1-33
• 71 Kling K, Harder T, Younger Z. et al Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety. J Travel Med 2020; 27: taaa016
• 72 AG Reiseimpfungen der Ständigen Impfkommission (STIKO): Kling K, Bogdan C, Burchard G et al. Wissenschaftliche Begründung für die Empfehlung zur Impfung gegen Japanische Enzephalitis bei Reisen in Endemiegebiete und für Laborpersonal. Epid Bull 2020; 18: 5-27
• 73 European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union One Health 2022 Zoonoses Report. EFSA J 2023; 21: e8442
• 74 Heitkamp C, Stelzl DR, Ramharter R. et al Rabies exposure in travellers to Asia, the Middle East, Africa, South and Central America – a German Airport study. J Travel Med 2020; 27: taaa058
• 75 Gautret P, Angelo KM, Asgeirsson H. et al Rabies post-exposure prophylaxis started during or after travel: A GeoSentinel analysis. PLoS Negl Trop Dis 2018; 12: e0006951
• 76 Henry RE, Blanton JD, Angelo KM. et al A country classification system to inform rabies prevention guidelines and regulations. J Travel Med 2022; 29: taac046
• 77 World Health Organization. Rabies Vaccines: WHO position paper – April 2018. Weekly epidemiological record 2018; 93: 201-220
• 78 Auswärtiges Amt. Vorgehen bei Kontakt mit tollwutverdächtigen Tieren im Ausland. 01/22. Im Internet:. https://www.auswaertiges-amt.de/blob/251026/63ede1f7da0361ace59b36be85951e9b/tollwutkontakt-data.pdf
• 79 GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019; 19: 369-381
• 80 Hancuh M, Walldorf J, Minta AA. et al Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction – Worldwide, 2018–2022. MMWR Morb Mortal Wkly Rep 2023; 72: 171-176
• 81 Falkenhorst G, Enkelmann J, Faber M. et al Zur Situation bei wichtigen Infektionskrankheiten – Importierte Infektionskrankheiten 2022. Epid Bull 2023; 46: 3-20
• 82 Yousafzai MT, Qamnar FN, Shakoor S. et al Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine. Clin Infect Dis 2019; 68 (Suppl 1) S16-S21
• 83 Posen HJ, Wong W, Farrar DS. et al Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions. J Travel Med 2023; 30: taac086
• 84 Carey ME, McCann NS, Gibani MM. Typhoid fever control in the 21st century: where are we now?. Curr Opin Infect Dis 2022; 35: 424-430
• 85 Meiring JE, Shakya M, Khanam F. et al Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. Lancet Glob Health 2021; 9: e1688-e1696
• 86 Faucher JF, Binder R, Missinou MA. et al Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 1147-1154
• 87 UK Health Security Agency. Typhoid: the green book, chapter 33. 3 April 2020. Im Internet:. https://www.gov.uk/government/publications/typhoid-the-green-book-chapter-33
• 88 Patel PD, Liang Y, Meiring JE. et al Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet 2024; 403: 459-468
• 89 Robert Koch-Institut. RSV-Infektionen. 02.02.2024. Im Internet:. https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_RSV.html
• 90 Ehl S, Bogdan C, Niehues T. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1034-1051
• 91 Niehues T, Bogdan C, Hecht J. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (I) Grundlagenpapier. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 674-684
• 92 Wagner N, Assmus F, Arendt G. et al Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 494-515
• 93 Chang L, Lim BCW, Flaherty GT. et al Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med 2019; 26: taz034
• 94 Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice. Rheumatology (Oxford) 2021; 60: 3969-3976
• 95 Robert Koch-Institut. Schutzimpfung gegen Gelbfieber: Häufig gestellte Fragen und Antworten. 16.1.2023. Im Internet:. https://www.rki.de/SharedDocs/FAQ/Impfen/Gelbfieber/FAQ-Liste_Gelbfieber_Impfen.html
• 96 Rosdahl A, Herzog C, Frösner G. et al An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study. Travel Med Infect Dis 2018; 21: 43-50
• 97 Eperon G, Bühler S, Enriquez N. et al [The immunosuppressed traveler: vaccination guidelines]. Rev Med Suisse 2018; 14: 922-933
• 98 Huber F, Ehrensperger B, Hatz C. et al Safety of live vaccines on immunosuppressive or immunomodulatory therapy – a retrospective study in three Swiss Travel Clinics. J Travel Med 2018; 25
• 99 Bühler S, Jaeger VK, Eperon G. et al Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy – a prospective multi-centre pilot study1. J Travel Med 2020; 27: taaa126
• 100 Wechsler ME, Souza-Machado A, Xu C. et al Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines. J Allergy Clin Immunol Glob 2021; 1: 9-15
• 101 Emi Aikawa N, Andrade Balbi V, Borba EF. et al Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine X 2021; 10: 100131